Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company pioneering targeted therapies for cancers driven by RAS mutations. This page serves as the definitive source for verified news and developments related to the company's precision oncology programs.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements in RAS pathway inhibition. Our curated collection includes press releases on drug discovery breakthroughs, partnership announcements, and peer-reviewed research findings.
Key focus areas include updates on the company's RAS(ON) inhibitor portfolio, mTOR signaling developments, and strategic collaborations advancing cancer treatment innovation. All content is vetted for accuracy and relevance to provide reliable insights into RVMD's evolving pipeline.
Bookmark this page for structured access to essential updates about Revolution Medicines' progress in addressing unmet needs in oncology through its evolution-inspired therapeutic approaches.
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its plan to release second quarter 2024 financial results on August 7, 2024, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and provide a corporate progress update. Interested parties can access the live webcast or replay through the company's investor relations website. The replay will be available for at least 14 days following the live event.
Revolution Medicines (Nasdaq: RVMD) announced the publication of a study in Cancer Discovery demonstrating the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977, in preclinical models of KRAS-mutated non-small cell lung cancer (NSCLC). The inhibitor showed strong anti-tumor activity alone and in combination with the RAS(ON) G12C-selective inhibitor, RMC-4998. This combination resulted in significant tumor regression and prolonged time to tumor doubling, particularly in models resistant to current therapies. The study also identified long-term tumor cell persistence mechanisms, providing insights for future treatments. Revolution Medicines plans to conduct further trials with their investigational drug RMC-6236, aimed at treating various RAS-driven cancers.
Revolution Medicines (Nasdaq: RVMD) will host an investor webcast to update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. The webcast is scheduled for July 15, 2024, at 8:00 a.m. Eastern Time. Speakers include the company's management and Dr. Brian M. Wolpin from Harvard Medical School and Dana-Farber Cancer Institute. The event can be accessed via the company's 'Events & Presentations' page. A replay will be available for 14 days post-event.
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focusing on targeted therapies for RAS-addicted cancers, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mark A. Goldsmith will present at a fireside chat on June 12, 2024, at 2:40 p.m. ET. The event will be held at the Loews Miami Beach Hotel in Miami, FL, with a live webcast accessible via the company's website. A replay will be available for 14 days post-conference.
Revolution Medicines, Inc. (Nasdaq: RVMD) released its first quarter 2024 financial results and corporate progress update. The company is advancing its RAS-addicted cancer therapies, such as RMC-6236, into pivotal trials. Plans include expanding therapy reach, qualifying mutant-selective inhibitors, and exploring combination treatments. Despite revenue decline and increased expenses, the company aims to fund operations into 2027.
Revolution Medicines, Inc. (Nasdaq: RVMD) will report its financial results for the first quarter of 2024 on May 8, 2024, after market close. The company is focused on developing targeted therapies for patients with RAS-addicted cancers. A webcast hosted by senior management will discuss the financial results and corporate progress.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
